Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST

Summary

This is an open-label, single-arm, multicenter expanded access study to provide patients who have locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST) and have received treatment with at least 2 prior Food and Drug Administration (FDA)-approved therapies early access to ripretinib until such time that ripretinib becomes commercially available or the Sponsor chooses to discontinue the program.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications